

Application Title: CELL LINE
Inventor: Charleata A. Carter Ph.D.
Serial No. 09/819,193
Filing Date: 03/28/2001
Attorney Docket No: 8263.003
Examiner: Karen A. Canela Ph.D.
ART UNIT NO. 1642

II. AMENDMENTS TO THE CLAIMS

Immediately following is a complete listing of all claims, with approved status identifiers.

21. (Currently amended) A hyperdiploid cellular composition comprising cells isolated from a poorly differentiated primary tumor of glandular epithelial cells of the endometrium of the uterus a ~~poorly differentiated human endometrial adenocarcinoma that is metastatic, said cells having characteristics consistent with primary tumor.~~

22. (Currently amended) A cellular composition as described in claim 21 hereinabove, wherein a plurality of said cells have at least an average of 48 chromosomes.

23. (Currently amended) A cellular composition as described in claim 22 hereinabove, wherein a plurality of said cells are at least triploid at chromosome 3.

24. (Currently amended) A cellular composition as described in claim 22 hereinabove, wherein a plurality of said cells are at least triploid at chromosome 17.

25. (Currently amended) A cellular composition as described in claim 21 hereinabove, wherein a plurality of said cells have at least the following karyotypic characteristics: 48, XX, ?t (1;20) (p?34.3; p11.2), dup (2) (q11.1q23), +3, del (5) (q723q?31), ?add(6) (p23), add (7) (p?21), +add (7) (q22), der(9;14) (q10;q10), add (15) (p11), +der (17) t(17;;19) (p11.1;p11.1), I (19) (q10), ?del (20)

Application Title: CELL LINE
Inventor: Charles A. Carter Ph.D.
Serial No. 09/819,193
Filing Date: 03/28/2001
Attorney Docket No: 8263.003
Examiner: Karen A. Canella Ph.D.
ART UNIT NO. 1642

(p?11.2).

26. (Currently amended) A line of cells originating from a primary tumor specimen of poorly differentiated human endometrial adenocarcinoma ~~that is metastatic, said cells having characteristics consistent with primary tumor,~~ wherein a plurality of said cells differentiates in response responds to an anti-cancer compound ~~in substantially equivalent ways at the cellular level as said specimen.~~

27. (Currently amended) A line of cells as described in claim 26 hereinabove, wherein said anti-cancer compound comprises a protein kinase inhibitor ~~differentiating agent.~~

28. (Currently amended) A line of cells as described in claim 27 hereinabove, wherein said ~~differentiating agent~~ protein kinase inhibitor comprises a retinoic acid treatment.

29. (Previously added) A cellular composition as described in claim 26 hereinabove, wherein said cells are grown *in vitro* as a monolayer.

30. (Cancelled) A cellular composition as described in claim 26 hereinabove, wherein said original specimen is superficially invasive.

31. (Withdrawn)

Application Title: CELL LINE
Inventor: Charleata A. Carter Ph.D.
Serial No. 09/819,193
Filing Date: 03/28/2001
Attorney Docket No: 8263.003
Examiner: Karen A. Canella Ph.D.
ART UNIT NO. 1642

32. (Withdrawn)

33. (Withdrawn)

34. (Withdrawn)

35. (Withdrawn)

36. (Withdrawn)

37. (Withdrawn)

38. (Withdrawn)

39. (Withdrawn)

40. (New) A cellular composition as described in claim 22 hereinabove, wherein a plurality of said cells are triploid at chromosome 7.

Application Title: CELL LINE
Inventor: Charicata A. Carter Ph.D.
Serial No. 09/819,193
Filing Date: 03/28/2001
Attorney Docket No: 8263.003
Examiner: Karen A. Canella Ph.D.
ART UNIT NO. 1642

41. (New) A cellular composition as described in claim 21 hereinabove, wherein a plurality of said cells are triploid at chromosomes 3, 7 and 17 but only haploid at chromosome 14.
42. (New) A cellular composition as described in claim 21 hereinabove, containing 48 chromosomes, wherein a plurality of said cells are triploid at chromosomes 3, 7 and 17 but only haploid at chromosome 14.
43. (New) A human endometrial adenocarcinoma cell line designated CAC-1 having all of the identifying characteristics of CAC-1 cells.